Yolanda Barbachano has been appointed as Head of Statistics for Quanticate.
Massive Bio announced the addition of two executives to its C-suite: Özgür “Oz” Huner as their first Chief Product Officer, and Erkan Terzi has been promoted to Chief Marketing Officer.
Encapsia announced the appointment of Francis Destin as its new Chief Operating Officer.
Dawn Sauro has been named as Elligo’s Chief Operating Officer.
Trialbee announced the addition of Kristopher Sarajian as their new Vice President of Marketing.
Greenphire has appointed Owen Newman as the Chief Financial Officer.
Emmes appointed Matt Honan as Vice President and Head of Corporate Development.
NNIT has received its recertification as a Veeva Premiere Services Partner – Development Cloud.
Suvoda LLC surpassed 1,000 clinical trials in 2022 as study deployments surged nearly 20%.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.